Collectively our results suggest that mitotic dysregulation is a key feature that contributes early to neuroblastoma tumor initiation and that a combination of antimitotic compounds and pro-apoptotic compounds offers synergistic therapeutic benefit in MYCN-driven neuroblastoma. This evidence concerns the gene MYCN and neuroblastoma.